Abiomed: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 3: | Line 3: | ||
{{Use mdy dates|date=October 2023}} | {{Use mdy dates|date=October 2023}} | ||
'''Abiomed''' is an American | [[File:ABIOMED_logo.svg|thumb|right|Abiomed logo]] | ||
'''Abiomed''' is an American medical device company that specializes in the development and manufacture of heart pumps. The company is known for its [[Impella]] heart pump technology, which is used to support patients with severe heart conditions. Abiomed is headquartered in [[Danvers, Massachusetts]]. | |||
==History== | ==History== | ||
Abiomed was founded in 1981 by Dr. David M. Lederman. The company initially focused on developing | Abiomed was founded in 1981 by Dr. David M. Lederman. The company initially focused on developing artificial hearts and circulatory support devices. Over the years, Abiomed has evolved to become a leader in the field of [[percutaneous]] heart pumps. | ||
==Products== | ==Products== | ||
Abiomed's primary product line is the Impella series of heart pumps. These devices are designed to provide temporary support to the heart | Abiomed's primary product line is the [[Impella]] series of heart pumps. These devices are designed to provide temporary support to the heart, allowing it to rest and recover. The Impella pumps are inserted percutaneously and can be used in various clinical settings, including during high-risk [[percutaneous coronary intervention]] (PCI) and in cases of [[cardiogenic shock]]. | ||
===Impella | ===Impella Heart Pumps=== | ||
The Impella heart pumps are small, catheter-based devices that are inserted through the femoral artery and positioned in the left ventricle. They work by drawing blood from the left ventricle and expelling it into the ascending aorta, thereby reducing the workload on the heart and improving cardiac output. | |||
==Research and Development== | ==Research and Development== | ||
Abiomed invests heavily in | Abiomed invests heavily in research and development to advance its heart pump technology. The company collaborates with leading medical institutions and participates in clinical trials to expand the indications for its devices and improve patient outcomes. | ||
==Corporate Structure== | ==Corporate Structure== | ||
Abiomed is a publicly traded company listed on the [[NASDAQ]] under the ticker symbol ABMD. The company has a global presence, with offices and facilities in | Abiomed is a publicly traded company listed on the [[NASDAQ]] stock exchange under the ticker symbol ABMD. The company has a global presence, with offices and facilities in several countries. | ||
==Impact on Cardiology== | |||
Abiomed's heart pump technology has had a significant impact on the field of cardiology. The Impella devices have been shown to improve survival rates in patients with severe heart conditions and have become an essential tool in the management of acute heart failure. | |||
==Related pages== | ==Related pages== | ||
* [[Heart | * [[Cardiology]] | ||
* [[ | * [[Heart failure]] | ||
* [[Percutaneous coronary intervention]] | |||
* [[Cardiogenic shock]] | * [[Cardiogenic shock]] | ||
[[Category:Medical device companies]] | [[Category:Medical device companies]] | ||
[[Category:Companies based in Massachusetts]] | [[Category:Companies based in Massachusetts]] | ||
[[Category:Companies established in 1981]] | [[Category:Companies established in 1981]] | ||
Latest revision as of 03:48, 13 February 2025
American medical device company specializing in heart pumps
Abiomed is an American medical device company that specializes in the development and manufacture of heart pumps. The company is known for its Impella heart pump technology, which is used to support patients with severe heart conditions. Abiomed is headquartered in Danvers, Massachusetts.
History[edit]
Abiomed was founded in 1981 by Dr. David M. Lederman. The company initially focused on developing artificial hearts and circulatory support devices. Over the years, Abiomed has evolved to become a leader in the field of percutaneous heart pumps.
Products[edit]
Abiomed's primary product line is the Impella series of heart pumps. These devices are designed to provide temporary support to the heart, allowing it to rest and recover. The Impella pumps are inserted percutaneously and can be used in various clinical settings, including during high-risk percutaneous coronary intervention (PCI) and in cases of cardiogenic shock.
Impella Heart Pumps[edit]
The Impella heart pumps are small, catheter-based devices that are inserted through the femoral artery and positioned in the left ventricle. They work by drawing blood from the left ventricle and expelling it into the ascending aorta, thereby reducing the workload on the heart and improving cardiac output.
Research and Development[edit]
Abiomed invests heavily in research and development to advance its heart pump technology. The company collaborates with leading medical institutions and participates in clinical trials to expand the indications for its devices and improve patient outcomes.
Corporate Structure[edit]
Abiomed is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ABMD. The company has a global presence, with offices and facilities in several countries.
Impact on Cardiology[edit]
Abiomed's heart pump technology has had a significant impact on the field of cardiology. The Impella devices have been shown to improve survival rates in patients with severe heart conditions and have become an essential tool in the management of acute heart failure.
